- Home
- STRO vs CRDL Comparison
STRO vs CRDL Comparison
Compare STRO & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CRDL
- Stock Information
- Founded
- STRO 2003
- CRDL 2017
- Country
- STRO United States
- CRDL Canada
- Employees
- STRO N/A
- CRDL N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STRO Health Care
- CRDL Health Care
- Exchange
- STRO Nasdaq
- CRDL Nasdaq
- Market Cap
- STRO 77.7M
- CRDL 80.1M
- IPO Year
- STRO 2018
- CRDL N/A
- Fundamental
- Price
- STRO $0.90
- CRDL $1.24
- Analyst Decision
- STRO Hold
- CRDL Strong Buy
- Analyst Count
- STRO 7
- CRDL 3
- Target Price
- STRO $5.47
- CRDL $9.33
- AVG Volume (30 Days)
- STRO 1.2M
- CRDL 150.7K
- Earning Date
- STRO 05-08-2025
- CRDL 05-14-2025
- Dividend Yield
- STRO N/A
- CRDL N/A
- EPS Growth
- STRO N/A
- CRDL N/A
- EPS
- STRO N/A
- CRDL N/A
- Revenue
- STRO $66,434,000.00
- CRDL N/A
- Revenue This Year
- STRO N/A
- CRDL N/A
- Revenue Next Year
- STRO N/A
- CRDL N/A
- P/E Ratio
- STRO N/A
- CRDL N/A
- Revenue Growth
- STRO N/A
- CRDL N/A
- 52 Week Low
- STRO $0.52
- CRDL $0.77
- 52 Week High
- STRO $5.17
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- STRO 50.82
- CRDL 61.96
- Support Level
- STRO $0.86
- CRDL $1.04
- Resistance Level
- STRO $0.99
- CRDL $1.31
- Average True Range (ATR)
- STRO 0.09
- CRDL 0.08
- MACD
- STRO 0.00
- CRDL 0.01
- Stochastic Oscillator
- STRO 68.44
- CRDL 74.26
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.